66051-76-1|Halofantrine, (-)-|3-(dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol|-范德生物科技公司

Halofantrine, (-)-

NMR下载 COA and HPLC MSDS下载
names：
3-(dibutylamino)-1-(1,3-dichloro-6-(trifluoromethyl)phenanthren-9-yl)propan-1-ol
CAS号：
66051-76-1
MDL Number：
MF(分子式)： C26H30Cl2F3NO MW(分子量)： 500.42
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)
FMK15963-100mg	100mg	>98%	¥ 0.00	¥ 0.00		Get quote	- +	¥ 0.00

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Halofantrine, (-)-
英文别名	Halofantrine, (-)-; L-WR-171669;
CAS号	66051-76-1
Inchi	InChI=1S/C26H30Cl2F3NO/c1-3-5-10-32(11-6-4-2)12-9-25(33)23-16-22-21(14-18(27)15-24(22)28)20-13-17(26(29,30)31)7-8-19(20)23/h7-8,13-16,25,33H,3-6,9-12H2,1-2H3
InchiKey	FOHHNHSLJDZUGQ-UHFFFAOYSA-N
分子式 Formula	C26H30Cl2F3NO
分子量 Molecular Weight	500.42
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Halofantrine, (-)-(CAS:66051-76-1):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Halofantrine, (-)- is an antimalarial drug.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1]Wesche DL, Schuster BG, Wang WX, Woosley RL. Mechanism of cardiotoxicity of halofantrine. Clin Pharmacol Ther. 2000 May;67(5):521-9. Review. PubMed PMID: 10824631.

[2]Peters W, Robinson BL, Ellis DS. The chemotherapy of rodent malaria. XLII. Halofantrine and halofantrine resistance. Ann Trop Med Parasitol. 1987 Oct;81(5):639-46. PubMed PMID: 3331253.

[3] ter Kuile FO, Dolan G, Nosten F, Edstein MD, Luxemburger C, Phaipun L, Chongsuphajaisiddhi T, Webster HK, White NJ. Halofantrine versus mefloquine in treatment of multidrug-resistant falciparum malaria. Lancet. 1993 Apr 24;341(8852):1044-9. PubMed PMID: 8096956.

[4] Singh N, Puri SK. Modulation of halofantrine resistance after coadministration of halofantrine with diverse pharmacological agents in a rodent malaria model. Life Sci. 2000 Aug 4;67(11):1345-54. PubMed PMID: 10972203.

[5] Karbwang J, Na Bangchang K. Clinical pharmacokinetics of halofantrine. Clin Pharmacokinet. 1994 Aug;27(2):104-19. Review. PubMed PMID: 7955774.

6: Kolade YT, Babalola CP, Olaniyi AA, Scriba GK. Effect of kolanut on the pharmacokinetics of the antimalarial drug halofantrine. Eur J Clin Pharmacol. 2008 Jan;64(1):77-81. Epub 2007 Oct 20. PubMed PMID: 17952423.7: Krishna S, ter Kuile F, Supanaranond W, Pukrittayakamee S, Teja-Isavadharm P, Kyle D, White NJ. Pharmacokinetics, efficacy and toxicity of parenteral halofantrine in uncomplicated malaria. Br J Clin Pharmacol. 1993 Dec;36(6):585-91. PubMed PMID: 12959277; PubMed Central PMCID: PMC1364665.8: Bassi PU, Onyeji CO, Ukponmwan OE. Effects of tetracycline on the pharmacokinetics of halofantrine in healthy volunteers. Br J Clin Pharmacol. 2004 Jul;58(1):52-5. PubMed PMID: 15206992; PubMed Central PMCID: PMC1884545.9: Brocks DR, Toni JW. Pharmacokinetics of halofantrine in the rat: stereoselectivity and interspecies comparisons. Biopharm Drug Dispos. 1999 Apr;20(3):165-9. PubMed PMID: 10211870.10: Mosqueira VC, Loiseau PM, Bories C, Legrand P, Devissaguet JP, Barratt G. Efficacy and pharmacokinetics of intravenous nanocapsule formulations of halofantrine in Plasmodium berghei-infected mice. Antimicrob Agents Chemother. 2004 Apr;48(4):1222-8. PubMed PMID: 15047523; PubMed Central PMCID: PMC375247.1

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开